# Insulin Glargine, INITIATE Metabolic and Economic Outcomes of Lantus

> **NCT00565162** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 124 (actual)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** Insulin Glargine

## Key facts

- **NCT ID:** NCT00565162
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** —
- **Final completion:** 2005-06
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2008-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00565162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00565162, "Insulin Glargine, INITIATE Metabolic and Economic Outcomes of Lantus". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00565162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*